Alert Your help is needed to shape the future of transplantation! This Giving Tuesday, help us send medical students and residents to the World Transplant Congress through our Early Trainee WTC Travel Grants
Skip to main

Astellas Receives FDA Approval for a New Product

Share

The U.S. Food and Drug Administration (FDA) recently approved the New Drug Application (NDA) for ASTAGRAF XL™ (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction. The full press release can be read here.

Give Back

Make a difference in the field of transplantation by donating to support our cause.

Give

Sign up for AST eNews

This resource for transplant professionals shares AST news events and top articles in transplantation.

View Current Issue

Advertisements

This content was developed independently by AST and supported by a financial contribution from Sanofi